Regulatory Press Releases

2021

2021-02-18 08:00 Stille AB: Year-End Report 2020 Regulatory MAR
Turnover for the fourth quarter increased to 45.0 MSEK (40.8) and operating profit to 8.7 MSEK (6.3). For the full year 2020, turnover reached 142.6 MSEK (156.7) and operating profit 10.2 MSEK (18.2). It has been a tough year, but it is great that we end the year with a historically strong quarter where all business areas and product lines display growth compared to previous year, says the CEO and...

2020

2020-10-29 08:00 Stille AB: Interim Report Q3 2020 Regulatory MAR
Revenue in the third quarter decreased to 31.5 MSEK (40.7) and the operating profit to 2.6 MSEK (8.9) compared to the previous year. This after a tough start of the quarter affected by COVID-19, followed by a strong finish. The operating profit was positively impacted by economic relief packages relating to COVID-19 by 1.0 MSEK. After a tough start we are now seeing a gradual return of the demand for...
2020-08-20 08:00 Stille AB: Interim Report Q2 2020 Regulatory MAR
Revenue in the second quarter was negatively affected by COVID-19 and decreased by 20.4 percent compared to the same quarter previous year. Revenue amounted to 29.3 MSEK (36.8). The operating profit decreased to -1.5 MSEK (5.1) and was negatively impacted by items affecting comparability of 5.4 MSEK following depreciation of stock and a weakened US dollar. Simultaneously, the operating profit was positively...
2020-06-01 16:15 Niklas Carlén Appointed New CFO at Stille Regulatory MAR
Stille has appointed Niklas Carlén as the new CFO for the company and a member of the group management. Niklas Carlén has a Masters Degree of Science in Business Administration and Economics from Örebro University. He has for the past 15 years worked as a CFO at Calix, Swecon and TOOLS Sverige, most recently as the CFO at Eskilstuna Strängnäs Energi och Miljö. I am...
2020-04-29 13:00 Stille AB: First Quarter 2020 Regulatory MAR
The otherwise often stable business area Surgical Instruments grew by 8 percent compared to previous year, mostly attributed to increased sales in the US. While the quarter started off strong, sales were negatively affected in March due to market realignment from surgery to intensive care. Together, this amounted to a revenue of 36.8 MSEK for the first quarter. It is great to see the progress made...